High expression levels (2-5-fold above baseline) of the Nek2 kinase in a variety of highly aggressive solid tumors, including triple negative breast cancer, makes this kinase a high value target for developing anti-cancer drugs [19,20,21,22,23,24]. Here, NEK2 is linked to cancer.